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Abstract
Coronavirus disease 2019 (COVID-19), which initially began in China, has spread to other countries 
of Asia, Europe, America, Africa and Oceania, with the number of confirmed cases and suspected cases 
increasing each day. According to recently published research, it was found that the majority of the severe 
cases were elderly, and many of them had at least one chronic disease, especially cardiovascular dis-
eases. Angiotensin-converting enzyme inhibitors/angiotensin receptor blockers (ACEIs/ARBs) are the 
most widely used drugs for cardiovascular diseases. The clinical effect of ACEIs/ARBs on patients with 
COVID-19 is still uncertain. This paper describes their potential role in the pathogenesis of COVID-19, 
which may provide useful in the advice of cardiologists and physicians. (Cardiol J 2020; 27, 2: xx–xx)
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Introduction 
Since December 2019, a series of pneumonia 
cases of unknown etiology were reported in Wu-
han, Hubei province, China. A novel coronavirus 
named 2019 novel coronavirus (2019-nCoV) was 
identified by the Chinese Center for Disease 
Control and Prevention (CDC) from the throat 
swab sample of a patient and the disease was sub- 
sequently officially named COVID-19 by the 
World Health Organization. As of March 20, 2020, 
more than 240,000 people have been confirmed 
with COVID-19 across the world. A pandemic 
of the novel coronavirus has posed significant 
threats to international health and the economy 
[1, 2].
2019-nCoV is the seventh coronavirus that 
has been confirmed to infect humans. It has 50% 
genomic similarity to the Middle East respiratory 
syndrome coronavirus (MERS-CoV), 75–80% to 
the severe acute respiratory syndrome coronavi-
rus (SARS-CoV) and 96% to a coronavirus found 
in bats. 2019-nCoV encodes at least 27 proteins, 
including 15 non-structural proteins, 4 structural 
proteins, and 8 auxiliary proteins. Spike glycopro-
tein (S) which locates on the outer envelope of 
the virion is responsible for binding to the host 
receptor angiotensin-converting enzyme 2 (ACE2).
The majority of the severe patients diag-
nosed with COVID-19 were elderly. In a study of 
52 severe, adult patients, researchers found that 
the mean age of these patients was 60 years and 
40% of these patients had at least one chronic 
disease such as hypertension [3, 4]. Angiotensin- 
-converting enzyme inhibitors/angiotensin recep-
tor blockers (ACEIs/ARBs), which are the most
widely used drugs for hypertension. But whether
ACEIs/ARBs should be used in patients with
COVID-19 is still a question worthy of discussion.
This paper describes its potential role in the patho-
genesis of COVID-19, which may provide useful
advice for cardiologists and physicians.
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Renin–angiotensin system  
and multi-system inflammation
Renin, a protease that is generated primarily 
in the kidney, cleaves angiotensinogen to gener-
ate angiotensin I (AngI). Subsequently, a protease 
called angiotensin-converting enzyme (ACE) 
cleaves AngI to produce angiotensin II (AngII). 
AngII is a key effector of the renin–angiotensin 
system (RAS) and exerts biological functions 
through two receptors: AngII receptor type 1 
(AT1R) and AngII receptor type 2 (AT2R). AT1R is 
coupled to G protein-coupled receptor which can 
stimulate multiple signaling path-ways including 
tyrosine kinases, MAPK/ERK, Rho/ROCK kinase 
and PLCb/IP3/diacylglycerol. AT1R activation 
mediates catecholamine release from peripheral 
sympathetic neurons, inflammation via NF-kB ac-
tivation, ROS production through NADH/NADPH 
oxidese activity, apoptosis via toll-like receptor 4 
activation and lung fibroblast proliferation. ACE2, 
a homologue of ACE, is responsible for producing 
Ang(1–7) by cleaving AngII. Ang(1–7) binds and 
activates G protein-coupled Mas receptor to ex-
ert anti-inflammatory and anti-remodeling effects 
[5–7]. ACE2 is abundantly present in the epithelia 
of the lung and small intestine. It was also present 
in most arterial and venous endothelial cells and 
arterial smooth muscle cells [8–10]. In a study 
published recently, researchers found that the 
distribution of ACE2 is more widespread in males 
than in females: at least 5 different types of cells in 
the male lung express this receptor, while only 2~4 
types of cells in female lungs express the receptor. 
The ACE2/Ang(1–7)/Mas receptor pathway often 
serves to counter-regulate the pro-inflammatory, 
pro-fibrotic and pro-hyperresponsive effects of the 
ACE/AngII/AT1 receptor pathway. The imbalance 
between ACE/AngII/AT1 receptor pathway and 
ACE2/Ang(1–7)/Mas receptor pathway in the RAS 
will lead to multi-system inflammation (Fig. 1). 
And increased ACE and AngII are poor prognostic 
factors for severe pneumonia [11, 12].
Activation of the ACE2/Ang(1–7)/Mas recep-
tor pathway is also proven to play a possible role 
in cardio-protection. Ferreira firstly put forward 
that low concentrations of ANG-(1–7) produced a 
significant reduction of ischemia/reperfusion in-
duced cardiac arrhythmias in isolated rat hearts. In 
addition to influencing cardiac rhythm, ANG-(1–7) 
has a significant anti-remodeling effect in different 
models of cardiomyopathy. It may be concluded that 
Figure 1. The renin–angiotensin system and 2019-nCoV.
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an increased level of ANG-(1–7) may prevent heart 
dysfunction, inhibit oxidative stress, protect against 
cardiac hypertrophy, and attenuate left ventricular 
remodeling. Not only in the respiratory and cardio-
vascular system, but also anti-inflammatory effects 
of ACE2/Ang(1–7)/Mas receptor pathway in kidney, 
liver, central nervous system, endocrine system, and 
others have also been successively confirmed [13].
Renin–angiotensin system 
and COVID-19
2019-nCoV infects people via the Spike-ACE2 
binding pathway [14, 15]. The binding of 2019-
nCoV and ACE2 resulted in the exhaustion of 
ACE2 and then ACE2/Ang(1–7)/Mas receptor 
pathway was inhibited. The inhibition of this sys-
tem may lead to many pathophysiological changes. 
In an animal trial published in “Nature”, it showed 
that loss of ACE2 expression precipitated severe 
lung injury. They also performed a rescue experi-
ment by using recombinant human ACE2 protein 
(rhuACE2). The results showed that injection of 
rhuACE2 into acid-treated ACE2 knockout mice 
decreased the degree of acute lung injury which is 
assessed by lung elastance and pulmonary edema 
formation. When they injected rhuACE2 protein 
into acid-treated wild-type mice, lung function and 
edema formation were also rescued [16–18]. 
Of note, demonstrated herein, was that serum 
AngII level were extremely elevated in COVID-19 
patients. More importantly, plasma AngII levels 
were linked to disease severity and predicted a 
fatal outcome in these patients. To test whether 
Spike-Fc injections indeed affect the function of 
the RAS, researchers analyzed AngII levels in the 
lungs of Spike-Fc-treated mice. Notably, a significant 
increase was observed in AngII levels in the lung 
tissue of these mice. To further confirm wheth-
er Spike-Fc promotes lung disease pathogenesis 
through increased AngII, they blocked the AT1R with 
a specific inhibitor. The results showed that inhibi-
tion of the AT1R indeed attenuated acute severe lung 
injury and pulmonary edema in these mice [19, 20]. 
Taken together, it is concluded that 2019-nCoV can 
exaggerate acute lung failure through deregulation 
of the ACE/AngII/AT1 receptor pathway. Moreover, 
2019-nCoV Spike-mediated lung failure can be res-
cued by the inhibition of AT1R.
ACEIs/ARBs and COVID-19
According to the reasons described below, it 
may speculated that ACEIs/ARBs could be used in 
patients with COVID-19 to reduce the multi-system 
inflammation response and mortality by decreasing 
AngII level. But some researchers have proposed 
a different point of view. What is known is that 
2019-nCoV infects patients by the binding recep-
tor ACE2. Use of ACEIs/ARBs may contribute to 
an increased level of ACE2 which makes the virus 
more likely to invade cells [21, 22]. Some scientists 
have suggested using ACE2 inhibitor called N-(2-
-aminoethyl)-1 aziridine-ethanamine to block the
2019-nCoV spike protein-mediated cell fusion [23].
ACEIs/ARBs reduces the multi-system inflam-
mation response in patients with COVID-19. But it 
also provides the virus with more receptors. The 
clinical effect it brings needs prospective studies and 
clinical trials to confirm this. Some scientists have 
suggested that the most rapid approach for assessing 
its feasibility is to analyze clinical patient records to 
determine whether COVID-19 patients who were 
medicated with AT1R antagonists prior to their di-
agnosis had better disease outcome. If COVID-19 
patients medicated with AT1R antagonists have re-
duced pulmonary inflammatory response and lower 
mortality, this would support the notion that ACEIs/
ARBs confer protection from severe symptoms 
among 2019-nCoV infected individuals. Knowledge 
gained from such datamining of clinical records may 
prove that ACEIs/ARBs provides positive clinical 
effect evidence for COVID-19 patients [24].
Conclusions
ACEIs/ARBs might be an attractive thera-
peutic agent to treat COVID-19 patients with 
cardiovascular diseases by reducing the pulmonary 
inflammatory response. The fact that increased 
levels of ACE2 may provide 2019-nCoV with 
more receptors and make it easier to invade cells 
should not be ignored. More prospective studies 
and randomized clinical trials are needed to prove 
its clinical effect on COVID-19 patients.
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